Sec Form 4 Filing - Mendelson Daniel Newman @ CHAMPIONS ONCOLOGY, INC. - 2020-02-18

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Mendelson Daniel Newman
2. Issuer Name and Ticker or Trading Symbol
CHAMPIONS ONCOLOGY, INC. [ CSBR]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
C/O CHAMPIONS ONCOLOGY, INC., ONE UNIVERSITY PLAZA, SUITE 307
3. Date of Earliest Transaction (MM/DD/YY)
02/18/2020
(Street)
HACKENSACK, NJ07601
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/18/2020 M 10,000 A $ 5.46 103,121 D
Common Stock 02/18/2020 M 10,000 A $ 1.59 113,121 D
Common Stock 02/18/2020 M 10,000 A $ 3.21 123,121 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option to purchase Common Stock $ 5.46 ( 1 ) 02/18/2020 M 10,000 ( 1 ) ( 2 ) 11/02/2020 Common Stock 10,000 $ 5.46 0 D
Option to purchase Common Stock $ 1.59 ( 1 ) 02/18/2020 M 10,000 ( 1 ) ( 3 ) 11/01/2021 Common Stock 10,000 $ 1.59 0 D
Option to purchase Common Stock $ 3.21 ( 1 ) 02/18/2020 M 10,000 ( 1 ) ( 4 ) 10/31/2022 Common Stock 10,000 $ 3.21 0 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Mendelson Daniel Newman
C/O CHAMPIONS ONCOLOGY, INC.
ONE UNIVERSITY PLAZA, SUITE 307
HACKENSACK, NJ07601
X
Signatures
/s/ Daniel Mendelson 03/30/2020
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Effective August 11, 2015, the Issuer effected a 1-for-12 reverse stock split of the Issuer's Common Stock (the "Reverse Stock Split"). All share numbers and the exercise price of the warrants reported herein give effect to the Reverse Stock Split.
( 2 )The options vest and are exercisable over a nine month period, with vesting to occur on November 2, 2015, February 2, 2016, May 2, 2016 and August 2, 2016, respectively.
( 3 )The options vest and are exercisable over a nine month period, with vesting to occur on November 1, 2016, February 1, 2017, May 1, 2017 and August 1, 2017, respectively.
( 4 )The options vest and are exercisable over a nine month period, with vesting to occur on November 8, 2017, February 8, 2018, May 8, 2018 and August 8 2018, respectively.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.